DAX24.423 +1,3%Est505.646 +1,2%MSCI World4.330 +0,2%Top 10 Crypto16,55 +1,5%Nas22.850 +0,4%Bitcoin102.568 +1,6%Euro1,1720 -0,1%Öl64,12 -2,0%Gold3.851 -0,4%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
DroneShield A2DMAA Rheinmetall 703000 NVIDIA 918422 RENK RENK73 Siemens Energy ENER6Y Tesla A1CX3T Novo Nordisk A3EU6F Plug Power A1JA81 Bayer BAY001 Alibaba A117ME HENSOLDT HAG000 Lufthansa 823212 BASF BASF11 Deutsche Telekom 555750 thyssenkrupp 750000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX letztlich kräftig im Plus -- US-Börsen fester -- Tesla meldet Rekord-Auslieferungen -- BioNTech, DroneShield, Siemens Energy, Novo Nordisk, BYD, Rüstungsaktien, Wolfspeed, Stellantis im Fokus
Top News
Vonovia-Aktie: Experten empfehlen im September mehrheitlich den Kauf Vonovia-Aktie: Experten empfehlen im September mehrheitlich den Kauf
Alibaba-Aktie zieht kräftig an: JPMorgan hebt Kursziel an - KI-Synergien im Fokus Alibaba-Aktie zieht kräftig an: JPMorgan hebt Kursziel an - KI-Synergien im Fokus
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Northwest Biotherapeutics Aktie

Kaufen
Verkaufen
0,1960 EUR ±0,0000 EUR ±0,00 %
STU
1,31 EUR +0,11 EUR +8,89 %
LSE
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone

Marktkap.303,24 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1J5EY

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS66737P6007

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolNWBO

Northwest Biotherapeutics Aktien News

DatumMeistgelesen
PR NewswireNorthwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd.
PR NewswireNorthwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd.
PR NewswireNorthwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman
PR NewswireNorthwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman
finanzen.netNorthwest Biotherapeutics stellte Ergebnisse des abgelaufenen Quartals vor
PR NewswireNorthwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments
PR NewswireNorthwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments
finanzen.netNorthwest Biotherapeutics verkündete Quartalsergebnis zum jüngsten Jahresviertel
finanzen.netNorthwest Biotherapeutics legte die Bilanz zum abgelaufenen Quartal vor
PR NewswireNorthwest Biotherapeutics Announces $5 Million Convertible Note Financing and Standby Facility for Up to $50 Million Additional Financing
finanzen.netNorthwest Biotherapeutics: Bilanz zum abgelaufenen Quartal
PR NewswireNorthwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities
PR NewswireNorthwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities
PR NewswireNorthwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property
PR NewswireNorthwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property
finanzen.netNorthwest Biotherapeutics legte die Bilanz zum abgelaufenen Quartal vor
PR NewswireNorthwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors
PR NewswireNorthwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification
PR NewswireNorthwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification
PR NewswireNorthwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma
PR NewswireNorthwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma
PR NewswireNorthwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application
PR NewswireNorthwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Application
PR NewswireNorthwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Application
PR NewswireNorthwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board
PR NewswireNorthwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board
PR NewswireNorthwest Biotherapeutics Announces Completion of Prerequisites, and Plans for Submission of Marketing Authorization Application
PR NewswireNorthwest Biotherapeutics Announces Completion of Prerequisites, and Plans for Submission of Marketing Authorization Application
PR NewswireNorthwest Biotherapeutics and Advent BioServices Announce Receipt of License for Commercial Manufacturing at Sawston, U.K. Facility
PR NewswireNorthwest Biotherapeutics and Advent BioServices Announce Receipt of License for Commercial Manufacturing at Sawston, U.K. Facility
PR NewswireNorthwest Biotherapeutics Announces That It Has No Banking Relationship With SVB
PR NewswireNorthwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews 2022 Progress and Looks Forward to Strong 2023
PR NewswireNorthwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews 2022 Progress and Looks Forward to Strong 2023
PR NewswireNorthwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax®-L for Glioblastoma
PR NewswireNorthwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax®-L for Glioblastoma

Northwest Biotherapeutics News

Northwest Biotherapeutics News: auf dieser Seite finden Sie alle Northwest Biotherapeutics News und Nachrichten zur Northwest Biotherapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Northwest Biotherapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Northwest Biotherapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.